The 9 most recent market catalysts affecting $VNRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
VolitionRx's Nu.Q® NETs assay has been chosen as the exclusive biomarker for the DETECSEPS project, a €6.3 million (~$7.3 million) French government-funded initiative aimed at the …
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 65
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
VolitionRx announced the full cash pre-payment of a $7.5 million senior secured convertible promissory note to Lind Global Asset Management. This action is significant because it e…
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 85
VolitionRX shares are trading lower after the company filed a prospectus for an offering of 10 million shares.
The filing of a prospectus for a 10 million share offering by VolitionRX (VNRX) is a significant corporate catalyst. This move typically leads to share dilution, meaning each exist…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders
Volitionrx has filed a prospectus for the resale of up to 10 million common shares by existing selling shareholders. This is not a primary offering by the company to raise capital,…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 85
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx announced a 112% year-over-year revenue surge in H1 2026, reaching $1.4 million, driven by expansion in clinical and commercial operations. The company achieved key diag…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 75
VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary Milestone
VolitionRx (VNRX) announced a robust 112% year-over-year revenue growth for the first half of 2026, reaching $1.4 million. This significant financial improvement is coupled with su…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 75
VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients
VolitionRx announced the publication of a peer-reviewed paper in 'Critical Care Medicine' validating their Nu.Q NETs H3.1 biomarker as a predictor of mortality and organ dysfunctio…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate
VolitionRX (VNRX) reported Q2 earnings per share of $(0.85), significantly missing the analyst consensus of $(0.57), and sales of $398.657K, also missing the $482.667K estimate. Th…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
VolitionRx Announces That Results Utilizing Its Lateral Flow Prototype Are Highly Correlated With Results Utilizing Its Legacy Automated Nu.Q® NETs Test In Critically Ill Sepsis Patients
VolitionRx has announced a significant breakthrough with its lateral flow finger-prick prototype for Nu.Q® NETs, demonstrating high correlation with its existing automated test for…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.